To address this limitation, as displayed by previously trials in melanoma, sequential administration of anti-CTLA4 followed by anti-PD-1 treatment might synergize the effect of these two drugs and make the potential toxicity more controllable12,13. This evidence concerns the gene CTLA4 and melanoma.